Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 3Neoplasm Metastasis 2Urogenital Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1Lung Neoplasms 1Genital Neoplasms, Male 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Cyclophosphamide 18Trastuzumab 16Paclitaxel 15Taxes 11Doxorubicin 11Radiotherapy 7Lapatinib 6Albumin-Bound Paclitaxel 6Vorinostat 5Tamoxifen 5Docetaxel 5Carboplatin 5Capecitabine 5Bevacizumab 5Radiation 4Letrozole 4Immunohistochemistry 4Anastrozole 4sargramostim 3pegfilgrastim 3exemestane 3Magnetic Resonance Spectroscopy 3Immunoenzyme Techniques 3Granulocyte-Macrophage Colony-Stimulating Factor 3Granulocyte Colony-Stimulating Factor 3Fluorodeoxyglucose F18 3Flow Cytometry 3Filgrastim 3Chemotherapy, Adjuvant 3saponin QA-21V1 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Breast Neoplasms, Male × Suspensions × Clear all
NCT02751528 2025-01-13

QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

NantBioScience, Inc.

Phase 1 Terminated
3 enrolled 10 charts
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡